{
    "info": {
        "nct_id": "NCT04332367",
        "official_title": "Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab",
        "inclusion_criteria": "* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.\n* PS 0-1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Presence of a driver mutation that is susceptible to targeted therapy\n* Other active invasive malignancy requiring ongoing therapy\n* Grade 2 or higher sensory neuropathy\n* Evidence of untreated brain metastases\n* History of bleeding diatheses or recent, antecedent hemoptysis (> 1/2 teaspoon in prior 2 months)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* PS 0-1",
            "criterions": [
                {
                    "exact_snippets": "PS 0-1",
                    "criterion": "performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to 4-6 cycles of Pem/Carbo/Pembro",
                    "criterion": "prior exposure to Pem/Carbo/Pembro",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "cycles"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "cycles"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two",
                    "criterion": "progressive disease after maintenance therapy",
                    "requirements": [
                        {
                            "requirement_type": "maintenance therapy agent",
                            "expected_value": [
                                "Pemetrexed",
                                "Pembrolizumab",
                                "combination of Pemetrexed and Pembrolizumab"
                            ]
                        },
                        {
                            "requirement_type": "duration of maintenance therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "progressive disease",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older",
            "criterions": [
                {
                    "exact_snippets": "Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy)",
                    "criterion": "non-squamous non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": "non-squamous"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "Stage IV"
                        },
                        {
                            "requirement_type": "recurrence_status",
                            "expected_value": "recurrent after initial curative intent therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "in adults age 18 or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* History of bleeding diatheses or recent, antecedent hemoptysis (> 1/2 teaspoon in prior 2 months)",
            "criterions": [
                {
                    "exact_snippets": "History of bleeding diatheses",
                    "criterion": "bleeding diatheses",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recent, antecedent hemoptysis (> 1/2 teaspoon in prior 2 months)",
                    "criterion": "hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.5,
                                "unit": "teaspoon"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Grade 2 or higher sensory neuropathy",
            "criterions": [
                {
                    "exact_snippets": "Grade 2 or higher sensory neuropathy",
                    "criterion": "sensory neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of a driver mutation that is susceptible to targeted therapy",
            "criterions": [
                {
                    "exact_snippets": "Presence of a driver mutation",
                    "criterion": "driver mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "susceptible to targeted therapy",
                    "criterion": "driver mutation",
                    "requirements": [
                        {
                            "requirement_type": "susceptibility to targeted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of untreated brain metastases",
            "criterions": [
                {
                    "exact_snippets": "Evidence of untreated brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other active invasive malignancy requiring ongoing therapy",
            "criterions": [
                {
                    "exact_snippets": "Other active invasive malignancy requiring ongoing therapy",
                    "criterion": "other active invasive malignancy",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "invasiveness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requirement for ongoing therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}